pdufa.bio
HomeConferences › IDWeek

IDSA/SHEA/HIVMA IDWeek 2026

Updated ·next FDA decision on the calendar

Oct 21-24, 2026 · Washington, DC · Infectious disease.

DatesOct 21-24, 2026
LocationWashington, DC
Therapeutic focusInfectious disease
Biotech presenters tracked0

Biotech presenters

Presenter list populates as abstracts are released.

How IDWEEK stocks have traded historically

Median share-price move around a presentation, measured across 1425 all tracked conference presentations in our study (2017-2026), because our study holds fewer than 12 IDWEEK events on their own.
30 days before-0.03%  50% rose · n=1425
10 days before+0.63%  52% rose · n=1425
Presentation day-0.56%  44% rose · n=1425
5 days after-1.59%  39% rose · n=1425
10 days after-1.93%  40% rose · n=1425
Read the whole row, not just the first line: across this study stocks have drifted up into these meetings and down out of them, and the effect is largest in the smallest companies. Medians are shown because a handful of large moves pulls an average away from the typical case. This is a historical distribution for a cohort of companies, not a forecast for any single company, and not investment advice. Methodology and the full study.

FAQ

When is IDWEEK 2026?
IDSA/SHEA/HIVMA IDWeek 2026 runs October 21-24, 2026 in Washington DC, US. The date comes from the organiser's own announcement; check the organiser's site for the final programme.
Which biotech companies are presenting at IDWEEK 2026?
None sourced yet. We list a company as presenting only when its own SEC filing or press release commits to this edition -- abstract titles and rumours don't qualify. The conferences page updates as filings land.
Why do medical conference dates matter for biotech stocks?
Trial results are often presented first at medical meetings, so a company's announced presentation is a dated, public catalyst. We publish a study of how biotech stocks have historically traded into conference presentations on the research page; it is historical measurement, not a prediction, and none of this is investment advice.